Cover Image
Read Now

CADTH Canadian Drug Expert Committee recommendation: Apomorphine hydrochloride (Movapo -- Paladin Labs Inc.) indication : Parkinson's disease

The CADTH Canadian Drug Expert Committee (CDEC) recommends that apomorphine hydrochloride (apomorphine) be reimbursed for the acute, intermittent treatment of hypomobility "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) in patients with ad...

Full description

Bibliographic Details
Corporate Authors: CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) CADTH 2018, January 2018
Edition:Version 1.0
Series:CADTH common drug review
Subjects:
Insurance, Health, Reimbursement
Parkinson Disease / Drug Therapy
Canada
Antiparkinson Agents / Economics
Antiparkinson Agents / Therapeutic Use
Drug Costs
Apomorphine / Therapeutic Use
Apomorphine / Economics
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The CADTH Canadian Drug Expert Committee (CDEC) recommends that apomorphine hydrochloride (apomorphine) be reimbursed for the acute, intermittent treatment of hypomobility "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) in patients with advanced Parkinson's disease (PD), if the following criterion and conditions are met. Apomorphine should only be used as adjunctive therapy in patients who are receiving optimized PD therapy (levodopa and derivatives and dopaminergic agonists) and still experiencing "off" episodes. Patients treated with apomorphine should be under the care of a physician with experience in the diagnosis and management of PD. Reduction in price
Item Description:"Final."
Physical Description:1 PDF file (7 pages)

Similar Items